TY  - JOUR
AU  - Kim, Youn H
AU  - Ortiz Romero, Pablo Luis
AU  - Yonekura, Kentaro
PY  - 2018
DO  - 10.1016/s1470-2045(18)30379-6
SN  - 1470-2045
UR  - https://hdl.handle.net/20.500.14352/131106
T2  - The Lancet Oncology
AB  - Background: Cutaneous T-cell lymphomas are rare non-Hodgkin lymphomas with substantial morbidity and mortality in advanced disease stages. We compared the efficacy of mogamulizumab, a novel monoclonal antibody directed against C-C chemokine receptor...
LA  - eng
M2  - 1192
PB  - Lancet Oncology
TI  - Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
TY  - journal article
VL  - 19
ER  -